Bio-Rad Laboratoriesvs.Quest Diagnostics
BIO vs DGX · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Quest Diagnostics is about 2.9× larger than Bio-Rad Laboratories by market cap; Quest Diagnostics trades at the lower P/E (22.6 vs 47.1); year to date, Quest Diagnostics leads (+19.5% vs −2.3%).
Side by side
| BIO | DGX | |
|---|---|---|
| Market cap | $8B | $23.1B |
| Price | $296.11 | $207.44 |
| Today | −0.4% | −0.3% |
| Return YTD | −2.3% | +19.5% |
| Return 1Y | +13.9% | +21.0% |
| P/E | 47.1 | 22.6 |
| P/S | 3.1 | 2.1 |
| P/B | 1.2 | 3.1 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Bio-Rad LaboratoriesBIO
American manufacturer of products for clinical diagnostics and life science research — including blood typing and droplet digital PCR.
Full BIO profile →Quest DiagnosticsDGX
Nationwide clinical laboratory network for routine and advanced diagnostics.
Full DGX profile →More comparisons in Diagnostics
See where BIO and DGX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →